Hepatitis C in children in times of change

Current Opinion in Pediatrics

Volumn 27, Issue 5, 2015, Pages 614-618

  Baker, Robert D ^a   Baker, Susan S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

direct acting antiviral; hepatitis C virus; vertical transmission

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CHILD; CHILDHOOD DISEASE; DISEASE SURVEILLANCE; FINANCIAL MANAGEMENT; HEPATITIS C; HUMAN; INFECTION RISK; MEDICAL HISTORY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; VERTICAL TRANSMISSION; VIROLOGY; HEPACIVIRUS; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROGNOSIS; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME; WATCHFUL WAITING;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HEPACIVIRUS; HEPATITIS C; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84954027094     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000259     Document Type: Review

References (35)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-1342.
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatol 1999; 6:35-47.
3. Slowik MK, Jhaveri R, Hepatitis B. C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296-305.
4. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19:7880-7888.
5. Wen JW, Haber BA. Maternal-fetal transmission of hepatitis C infection: what is so special about babies? J Pediatr Gastroenterol Nutr 2014; 58:278-282.
6. Serranti D, Buonsenso D, Ceccarelli M, et al. Pediatric hepatitis C infection: to treat or not to treat..what's the best for the child? Eur Rev Med Pharmacol Sci 2011; 15:1057-1067.
7. Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54:838-855.
8. Baker R. Viral Hepatitis. In: Pohl JF, editor. Pediatric gastroenterology. Baton Rouge, FL: CRC Press; 2014. pp. 313-327.
9. Le Campion A, Larouche A, Fauteux-Daniel S, et al. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012; 4:3531-3550.
10. Oketani M, Shibatou T, Yamashita K, et al. Postpartum acute exacerbation of chronic hepatitis C with complete response to interferon-alpha. J Gastro-enterol 2002; 37:658-662.
11. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163:1549-1552; e1.
12. Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-to-child transmission of HCV infection. Virology 2009; 390:64-70.
13. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:109-113.
14. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The vertical transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744-750.
15. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15250 pregnant women. Hepatology 2000; 31:751-755.
16. Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014; 173:1025-1031.
17. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134:1900-1907.
18. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53:1830-1838.
19. Kage M, Fujisawa T, Shiraki K, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26:771-775.
20. Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28:1416-1423.
21. Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168-174; e1.
22. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003; 98:660-663.
23. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41:845-851.
24. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48:341-347.
25. Deschesnes M, Demers S. Fines P Prevalence and characteristics of body piercing and tattooing among high school students. Can J Public Health 2006; 97:325-329.
26. Jafari S, Copes R, Baharlou S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010; 14:e928-e940.
27. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
28. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. NEngl JMed 2014; 370:1594-1603.
29. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
30. Bell TW. Drugs for hepatitis C unlocking a new mechanism of action. Chem Med Chem 2010; 5:1663-1665.
31. Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55:1620-1628.
32. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6:3-16.
33. Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53:1377-1385.
34. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
35. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-232.